XBiotech Faces Class Action Over Drug Study Problems
Law360, Chicago (December 3, 2015, 3:33 PM EST) -- XBiotech Inc. was hit with a putative class action in California state court by a group of shareholders who invested in the pharmaceutical company following its initial public offering, claiming the company misstated progress in European clinical studies for its primary product.
In a prospectus filed along with its public offering, Canada-based XBiotech said it expected enrollment in the study to be complete in the second half of 2015, but instead announced in November that a large number of patients enrolled in the study had dropped out or failed to properly complete all testing, according to the suit filed Tuesday....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!